Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Bipolar I Disorder
Clinical trial register · United States · industry-sponsored

Bipolar I Disorder Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9159 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Oct 2026, 03:16 UTC
9159
Studies in scope
industry-sponsored, all four open statuses
4969
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
Arkansas 9 California 9 Florida 9 Georgia 9 Illinois 6
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Bipolar I Disorder trials in the USA

11 of 9159 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
AbbVie
Phase 2
195
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri
2026-02-03
Recruiting
LB Pharmaceuticals Inc.
Phase 2
320
Arkansas, California, Florida, Georgia, Illinois, Michigan, Missouri, Nevada
2026-01-23
Recruiting
Neurocrine Biosciences
Phase 2
150
Arkansas, California, Florida, Georgia, Maryland, New Jersey, New York, Texas
2025-12-24
Active, closed
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
NCT07217860Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
Xenon Pharmaceuticals Inc.
Phase 3
400
Arkansas, California, Florida, Georgia, Illinois, New Jersey, New York, Pennsylvania
2025-10-30
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
400
Arizona, Arkansas, California, Florida, Georgia, Illinois, Missouri, Nevada
2025-08-08
Recruiting
Vanda Pharmaceuticals
Phase 4
100
Alabama, Arkansas, Colorado, Georgia, North Carolina, Ohio, Washington
2023-05-24
Recruiting
Alkermes, Inc.
Phase 3
220
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-06-30
By invitation
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
NCT04987229Bipolar I Disorder, Schizophrenia
Alkermes, Inc.
Phase 3
236
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2021-10-22
Recruiting
AbbVie
Phase 3
380
Arkansas, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2021-04-28
Active, closed
ERG Components in Schizophrenia and Bipolar Disorder Type I
NCT03788811Schizophrenia, Bipolar I Disorder
diaMentis Inc.
Observational
300
California, Florida, Massachusetts, New Jersey, New York, Texas
2018-07-05
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/bipolar-i-disorder

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,159 studies in total at the last sync on 25 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies listing the condition Bipolar I Disorder.

How many Bipolar I Disorder trials are recruiting in the US?

7 of the 11 studies on this page are recruiting new participants as of the 25 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bipolar I Disorder), 11 studies
PhaseStudiesRecruitingShare
Phase 35245.5%
Phase 23327.3%
Observational109.1%
Phase 1/2119.1%
Phase 4119.1%

Most active sponsors

Lead sponsors with the most studies (Bipolar I Disorder)
Lead sponsorStudiesRecruiting
AbbVie22
Alkermes, Inc.21
Xenon Pharmaceuticals Inc.20
Alzamend Neuro, Inc.11
diaMentis Inc.10
LB Pharmaceuticals Inc.11
Neurocrine Biosciences11
Vanda Pharmaceuticals11

Top states

Top states (Bipolar I Disorder), by number of studies with a site there
StateStudies
Arkansas9
California9
Florida9
Georgia9
Illinois6
Alabama4
Missouri3
New Jersey3
New York3
Arizona2
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.